Alpha 1-antitrypsin deficiency natural history, complications, and prognosis: Difference between revisions
m (Anthony Gallo moved page Alpha 1-antitrypsin deficiency natural history to Alpha 1-antitrypsin deficiency natural history, complications, and prognosis) |
Mazia Fatima (talk | contribs) No edit summary |
||
Line 14: | Line 14: | ||
==Complications== | ==Complications== | ||
Common complications of AATD include | |||
* pneumothorax | |||
* pneumonia | |||
* acute exacerbation of airflow obstruction | |||
* respiratory failure. | |||
* [[Bronchiectasis]] | * [[Bronchiectasis]] | ||
* [[Cirrhosis]] or [[liver failure]] | * [[Cirrhosis]] or [[liver failure]] | ||
Line 20: | Line 26: | ||
==Prognosis== | ==Prognosis== | ||
Prognosis depends on how patients are identified. Patients identified as a result of screening often have excellent prognosis. | |||
Those identified because of their symptoms have poor prognosis. | |||
Features associated with poor prognosis include: | |||
* Severe degree of airflow obstruction: | |||
* FEV 1 >50% has a 5-y mortality rate at 4%; | |||
* FEV 1 within range 35-49% has 5-y mortality rate at 12%; | |||
* FEV 1 <35 has a 5-y mortality rate at 50% | |||
* A bronchodilator response greater than >12%. | |||
* Smoking | |||
* Male sex | |||
==References== | ==References== |
Revision as of 11:12, 12 December 2017
Alpha 1-antitrypsin deficiency Microchapters |
Differentiating Alpha 1-antitrypsin deficiency from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Alpha 1-antitrypsin deficiency natural history, complications, and prognosis On the Web |
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency natural history, complications, and prognosis |
FDA on Alpha 1-antitrypsin deficiency natural history, complications, and prognosis |
CDC on Alpha 1-antitrypsin deficiency natural history, complications, and prognosis |
Alpha 1-antitrypsin deficiency natural history, complications, and prognosis in the news |
Blogs on Alpha 1-antitrypsin deficiency natural history, complications, and prognosis |
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Alpha 1-antitrypsin deficiency (A1AD) may be slow to manifest in symptom onset in newborns. As a patient ages, liver dysfunction and deterioration will occur. Mortality is directly related to the respiratory failure caused by a fall in forced expiratory volume.
Natural History
- Within the first two decades of life, liver dysfunction tends to dominate the clinical picture, while lung function is generally preserved.
- Two prospective studies have followed newborns identified at birth with blood screening for up to 16 years, and both showed no difference in lung function compared with controls.
- After the first 20 years, however, lung function begins to deteriorate at the rate mentioned above.
Respiratory failure accounts for ~ 62% of deaths, and complications of chronic liver disease for ~ 13%. The mean age of death in one study was 53 years old for nonsmokers and 40 years old for smokers, with only 16% surviving to 60 years old. This compares to ~ 85% surviving to 65 years old in the general population. Mortality is directly related to FEV1 (forced expiratory volume), and rises exponentially as FEV1 falls below 35% predicted. In a Danish study, asymptomatic nonsmokers, who were identified as relatives of symptomatic patients with alpha-1 AT had a normal life expectancy. This is consistent with the presence of a subgroup of patients with severe deficiency in alpha-1 AT who escape medical attention.
Complications
Common complications of AATD include
- pneumothorax
- pneumonia
- acute exacerbation of airflow obstruction
- respiratory failure.
Prognosis
Prognosis depends on how patients are identified. Patients identified as a result of screening often have excellent prognosis.
Those identified because of their symptoms have poor prognosis.
Features associated with poor prognosis include:
- Severe degree of airflow obstruction:
- FEV 1 >50% has a 5-y mortality rate at 4%;
- FEV 1 within range 35-49% has 5-y mortality rate at 12%;
- FEV 1 <35 has a 5-y mortality rate at 50%
- A bronchodilator response greater than >12%.
- Smoking
- Male sex